Patents by Inventor Suzanne Suchard
Suzanne Suchard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295321Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, Pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.Type: ApplicationFiled: September 21, 2022Publication date: September 21, 2023Inventors: MAREK HONCZARENKO, VAISHALI SHAH, LIXIN LANG, URVI ARAS, DIANE SHEVELL, CHRISTINE KRATT, KAREN PRICE, SUZANNE SUCHARD
-
Patent number: 11466091Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.Type: GrantFiled: February 20, 2020Date of Patent: October 11, 2022Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Marek Honczarenko, Vaishali Shah, Lixin Lang, Urvi Aras, Diane Shevell, Christine Kratt, Karen Price, Suzanne Suchard
-
Patent number: 11136406Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: GrantFiled: December 20, 2019Date of Patent: October 5, 2021Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20200216552Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.Type: ApplicationFiled: February 20, 2020Publication date: July 9, 2020Inventors: Marek Honczarenko, Vaishali Shah, Lixin Lang, Urvi Aras, Diane Shevell, Christine Kratt, Karen Price, Suzanne Suchard
-
Publication number: 20200199244Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: December 20, 2019Publication date: June 25, 2020Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
-
Patent number: 10544228Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: GrantFiled: September 8, 2016Date of Patent: January 28, 2020Assignees: Bristol-Myers Squibb Company, Domantis LimitedInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20170306034Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.Type: ApplicationFiled: September 10, 2015Publication date: October 26, 2017Inventors: Marek HONCZARENKO, Vaishali SHAH, Lixin LANG, Urvi ARAS, Diane SHEVELL, Christine KRATT, Karen PRICE, Suzanne SUCHARD
-
Publication number: 20170015754Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: September 8, 2016Publication date: January 19, 2017Inventors: Anish SURI, Steven SHERIFF, Suzanne SUCHARD, Aaron YAMNIUK, Stanley KRYSTEK, James TAMURA, James BRYSON, Steven GRANT, Philip DREW
-
Patent number: 9475879Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: GrantFiled: April 20, 2012Date of Patent: October 25, 2016Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITEDInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20140099317Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).Type: ApplicationFiled: April 20, 2012Publication date: April 10, 2014Applicants: DOMANTIS LIMITED, BRISTOL-MYERS SQUIBB COMPANYInventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
-
Publication number: 20060014180Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: ApplicationFiled: June 2, 2005Publication date: January 19, 2006Inventors: Donald Jackson, Chandra Ramanathan, John Feder, Gabe Mintier, Liana Lee, Thomas Nelson, Nathan Siemers, David Bol, Suzanne Suchard, Gary Schieven, Joshua Finger, C. Todderrud, Donna Bassolino, Stanley Krystek, Dana Banas, Patrick McAtee
-
Patent number: 6939896Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection.Type: GrantFiled: December 18, 2000Date of Patent: September 6, 2005Assignee: AstraZeneca ABInventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Publication number: 20050130286Abstract: The present invention provides novel polynucleotides encoding human phosphatase polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel human phosphatase polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: ApplicationFiled: December 20, 2001Publication date: June 16, 2005Inventors: Donald Jackson, Chandra Ramanathan, John Feder, Gabe Mintier, Liana Lee, Thomas Nelson, Nathan Siemers, David Bol, Suzanne Suchard, Gary Schieven, Joshua Finger, C. Todderrud, Donna Bassolino, Stanley Krystek, Dana Banas, Patrick McAtee
-
Publication number: 20030207812Abstract: Substituted phenanthrene-9,10-diones in accord with structural diagram I, 1Type: ApplicationFiled: November 25, 2002Publication date: November 6, 2003Inventors: Marc Jerome Chapdelaine, Katharine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Publication number: 20030130298Abstract: Heterocyclic dione compounds as disclosed in the specification, compositions thereof and methods for the use thereof, for the treatment of T cell-mediated conditions such as autoimmune diseases and organ graft rejection.Type: ApplicationFiled: November 25, 2002Publication date: July 10, 2003Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale
-
Publication number: 20030119897Abstract: Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.Type: ApplicationFiled: November 13, 2002Publication date: June 26, 2003Inventors: Marc Jerome Chapdelaine, Katherine Knappenberger, Gary Steelman, Suzanne Suchard, Linda Sygowski, Rebecca Urbanek, Chris Allan Veale